Announcement PDF ASX RELEASE 23 October 2026 Deferral of AGM and Financial Reporting Obligations Deferral of Obligations Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX: PAR) (Company) refers to the appointment of Christopher Pattinson and Hayden White of FTI Consulting as Joint and Several Voluntary Administrators (Administrators) of the Company on 29 September 2026 2026 under section 436A of the Corporations Act 2001 (Cth) (Act). The Company gives notice that it intends to rely on the relief in sections 8 and 9 of ASIC Corporations (Externally-Administered Bodies) Instrument 2025/584 (Instrument), which provides for the deferral of: • the Company's financial reporting obligations under Part 2M.3 of the Corporations Act 2001 (Cth) (Act); and • the requirement under section 250N of the Act for the Company to hold an Annual General Meeting (AGM). IMPORTANT: The Company’s 2026 Annual General Meeting, which would otherwise be required to be held by 30 November 2026, has been deferred and will not be held by that date. Annual Report for the financial year ended 30 June 2026 Prior to the appointment of the Administrators, the Company released its Annual Report for the financial year ended 30 June 2026 (2026 Annual Report) to ASX on 28 August 2026. The 2026 Annual Report remains available on the ASX announcements platform and on the Company’s website at www.paradigmbiopharma.com. As the Company’s 2026 AGM has been deferred (see below), the 2026 Annual Report will be laid before the deferred AGM to be held in accordance with the Instrument. Deferral Period Under the Instrument, the relief applies for the following period (Deferral Period): (a) if the external administration of the Company ends on or before 29 March 2027 (being 6 months after the appointment of the Administrators): the period starting on 29 September 2026 and ending on 29 March 2027; or (b) if the Company remains under external administration on 30 March 2027: the period starting on 29 September 2026 and ending on the earliest of: (i) 29 September 2028 (being 24 months after the appointment of the Administrators); (ii) if a deed administrator is appointed following the appointment of the Administrators - the day (if any) on which a director of the Company has the right to, or is able to, perform or exercise all or most of the management powers or functions of a director of the Company under the deed of company arrangement or with the consent of the deed administrator; and (iii) the day the external administration of the Company ends. Deferral of Financial Reporting Obligations Subject to the conditions in section 8 of the Instrument, the Company does not have to comply with any of the following requirements of Part 2M.3 of the Act in relation to a financial year or half-year of the Company, where the requirement would otherwise have arisen within 24 months after the appointment of the Administrators: (a) the requirement to prepare a financial report and directors’ report for a financial year under paragraphs 292(1)(b) and (c) and paragraph 292(2)(b) of the Act; (b) the requirement to have the financial report for a financial year audited and to obtain an auditor’s report under subsection 301(1) of the Act; (c) the requirement to report to members under section 314 of the Act within the time required by section 315 of the Act; (d) the requirement to send reports to a member in accordance with a request under subsection 316(1) of the Act within the time required by subsection 316(2) of the Act; (e) the requirement to send reports to a member in accordance with a request under subsection 316A(1) of the Act within the time required by subsection 316A(3) of the Act; (f) the requirement to lodge reports with ASIC under subsection 319(1) of the Act within the time required by subsection 319(3) of the Act; (g) the requirement to prepare a financial report and directors’ report for a half-year under paragraph 302(a) of the Act; (h) the requirement to have the financial report for a half-year audited or reviewed and to obtain an auditor’s report under paragraph 302(b) of the Act; and (i) the requirement to lodge reports for a half-year with ASIC under paragraph 302(c) and subsection 320(1) of the Act within the time required by subsection 320(1) of the Act, (together, the Financial Reporting Obligations). The relief also extends to any continuing Financial Reporting Obligation in relation to an earlier financial year or half- year of the Company, to the extent that obligation continues from the date of appointment of the Administrators. This includes the Company’s half-year financial report for the half-year ending 31 December 2026, which would otherwise be required to be lodged by 16 March 2027. The Company must comply with any deferred Financial Reporting Obligations by no later than the last day of the Deferral Period. DRAFT FOR REVIEW | NOT AUTHORISED FOR RELEASE Deferral of Annual General Meeting Subject to the conditions in section 9 of the Instrument, the Company does not have to comply with the requirement under section 250N of the Act to hold an AGM: (a) at least once in each calendar year and within 5 months after the end of its financial year; or (b) in relation to any earlier financial year of the Company, to the extent that section 250N of the Act would have imposed a continuing obligation on the Company on or after the appointment of the Administrators, where the Company would otherwise be required to hold an AGM during the Deferral Period. Accordingly, the Company’s 2026 AGM, which would otherwise have been required to be held by 30 November 2026, will not be held by that date. In accordance with the Instrument, the Company must: (a) hold an AGM within 2 months after the end of the Deferral Period; and (b) lay before that AGM all outstanding financial reports, including the 2026 Annual Report and any financial reports deferred under section 8 of the Instrument. Shareholder questions The Company has arrangements in place to answer, within a reasonable period of time and without charge, any reasonable questions from shareholders about the external administration of the Company and the Company’s obligations to hold any AGM not held during the Deferral Period. Shareholders may direct questions to the Administrators at shane.murphy@fticonsulting.com or on +61 8 9321 8533. Further information This notice will be published on the ASX announcements platform, on the Company’s website at www.paradigmbiopharma.com and on the Administrators’ website at https://www.fticonsulting.com/creditors/paradigm-biopharmaceuticals-limited- administrators-appointed. Further information in relation to the administration will be made available on those websites. -Ends- Authorised for release by the Administrators*. To learn more please visit: www.paradigmbiopharma.com FOR FURTHER INFORMATION PLEASE CONTACT: Media Enquiries Creditor and Supplier Enquiries Investor Shane Murphy Strategic Communications FTI Consulting T: +61 (0) 420 945 291 E: shane.murphy@fticonsulting.com James Dunne Corporate Finance FTI Consulting T: +61 8 6430 1303 E: James.Dunne@fticonsulting.com Simon White Director of Investor Relations Paradigm Biopharma T: +61 404 216 467 E: investorrelations@paradigmbiopharma.com *Christopher Pattinson and Hayden White of FTI Consulting were appointed as joint and several voluntary administrators of Paradigm Biopharmaceuticals Limited (Administrators Appointed) ACN 169 346 963 on 29 September 2026.